Core Viewpoint - Zhonghui Biotech-B (02627) has seen a stock price increase of over 3%, currently trading at 50.4 HKD with a transaction volume of 5.0766 million HKD, following the approval of its quadrivalent influenza virus subunit vaccine by the National Medical Products Administration of China [1][1][1] Group 1 - The company announced that its quadrivalent influenza virus subunit vaccine has received approval for the 6-35 month age group, making it the first and only vaccine of its kind approved for the entire population in China [1][1] - The new vaccine represents a significant upgrade over traditional virus split vaccines, offering comprehensive protection, high purity of antigen components, and lower risk of adverse reactions [1][1][1]
港股异动 | 中慧生物-B(02627)涨超3% 四价流感病毒亚单位疫苗上市申请获国家药监局批准